Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophiliaA mice and dogs

Blood

Volumn 119, Issue 13, 2012, Pages 3024-3030

  Dumont, Jennifer A ^a   Liu, Tongyao ^a   Low, Susan C ^a   Zhang, Xin ^a   Kamphaus, George ^a   Sakorafas, Paul ^a   Fraley, Cara ^a   Drager, Douglas ^a   Reidy, Thomas ^a   McCue, Justin ^a   Franck, Helen W G ^b   Merricks, Elizabeth P ^b   Nichols, Timothy C ^b   Bitonti, Alan J ^a   Pierce, Glenn F ^a   Jiang, Haiyan ^a  

^a BIOGEN   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMATOLOGIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8 FC FUSION PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING TIME; CELL STRAIN HEK293; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; HEMOPHILIA A; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SURFACE PLASMON RESONANCE;

EID: 84859192874     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-367813     Document Type: Article

References (44)

1. Mannucci PM, Tuddenham EG. The hemophilias- from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779. (Pubitemid 32497033)
2. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544. (Pubitemid 47236278)
3. Ljung RC. Prophylactic treatment in Sweden- overtreatment or optimal model? Haemophilia. 1998;4(4):409-412. (Pubitemid 28351855)
4. White GC, 2nd Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost. 1997;77(4):660-667.
5. Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia. 2003;9(suppl 1):101-108, discussion 109-110.
6. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol. 2000;18:739-766. (Pubitemid 30365396)
7. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7(9):715-725. (Pubitemid 47327396)
8. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant. 2006;6(5 Pt 1):876-883. (Pubitemid 44356637)
9. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9(1): 47-52. (Pubitemid 36098259)
10. Cines DB, Yasothan U, Kirkpatrick P. Romiplostim. Nat Rev Drug Discov. 2008;7(11):887-888.
11. Dumont JA, Low SC, Peters RT, Bitonti AJ. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. Bio- Drugs. 2006;20(3):151-160. (Pubitemid 43845335)
12. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP. Delivery of an erythropoietin- Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med. 2005;18(3):294-303. (Pubitemid 41395731)
13. Bitonti AJ, Dumont JA, Low SC, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A. 2004;101(26):9763-9768. (Pubitemid 38869310)
14. Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 2010;115(10):2057-2064.
15. Salas J, Liu T, Kistanova E, et al. Enhanced pharmacokinetics of factor VIIa as a monomeric FC fusion. J Thromb Haemost. 2011;9(s2):268: Abstract O-TU-026.
16. McCue JT, Selvitelli K, Walker J. Application of a novel affinity adsorbent for the capture and purification of recombinant factor VIII compounds. J Chromatogr A. 2009;1216(45):7824-7830.
17. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10(1):119-121.
18. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington DC: National Academy Press; 1996.
19. Graham JB, Buckwalter JA, et al. Canine hemophilia; observations on the course, the clotting anomaly, and the effect of blood transfusions. J Exp Med. 1949;90(2):97-111.
20. Lozier JN, Dutra A, Pak E, et al. The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. Proc Natl Acad Sci U S A. 2002; 99(20):12991-12996.
21. Pan J, Liu T, Kim JY, et al. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. Blood. 2009;114(13):2802-2811.
22. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999; 5(1):56-63. (Pubitemid 29050999)
23. Butenas S, Mann KG. Blood coagulation. Biochemistry. 2002;67(1):3-12.
24. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood. 1990;75(10):1999- 2004. (Pubitemid 20180289)
25. Shen BW, Spiegel PC, Chang CH, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood. 2007. 2008;111(3):1240-1247.
26. Ngo JC, Huang M, Roth DA, Furie BC, Furie B. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure. 2008;16(4):597-606. (Pubitemid 351458707)
27. Borvak J, Richardson J, Medesan C, et al. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol. 1998;10(9):1289-1298. (Pubitemid 28414334)
28. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol. 2007;179(7):4580-4588.
29. Yoshida M, Claypool SM, Wagner JS, et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity. 2004; 20(6):769-783. (Pubitemid 38757446)
30. Lenting PJ, CJ VANS, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5(7):1353-1360. (Pubitemid 46965358)
31. van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood. 2008;112(5):1704-1712.
32. Rostin J, Smeds AL, Akerblom E. B-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol. Bioconjug Chem. 2000;11(3):387-396. (Pubitemid 30324905)
33. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116(2):270-279.
34. Moss J, Rosholm A, Lauren A. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost. 2011;9(7):1368-1374.
35. Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011.
36. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009;102(4):634-644.
37. Weimer T, Wormsbacher W, Kronthaler U, Lang W, Liebing U, Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost. 2008;99(4):659-667. (Pubitemid 351694221)
38. Liu T, Lillicrap D, Zhang X, et al. Site-specific PEGylation of factor VIII (PEG-FVIII) preserves full clotting activity and extends therapeutic efficacy in hemophiliaA dogs [abstract]. Blood. 2008; 112(22):Abstract 511.
39. Karpf DM, Kjalke M, Olsen EHN, et al. Preclinical pharmacokinetic (PK) evaluation of glycopegylated long acting rFVIII. Haemophilia. 2010; 16(suppl s4):40.
40. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119(13):3031-3037.
41. Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood. 2005;105(12):4865-4870. (Pubitemid 40812408)
42. De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes." Blood. 2008;112(8): 3303-3311.
43. Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21(24):3365-3369. (Pubitemid 36792087)
44. Grubb JH, Vogler C, Tan Y, Shah GN, MacRae AF, Sly WS. Infused Fc-tagged betaglucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice. Proc Natl Acad Sci U S A. 2008;105(24):8375-8380. (Pubitemid 351904763)